Clinical and microbiological effects of levofloxacin in the treatment of chronic periodontitis: a randomized, placebo-controlled clinical trial
Article first published online: 27 FEB 2014
© 2014 Wiley Publishing Asia Pty Ltd
Journal of Investigative and Clinical Dentistry
Volume 6, Issue 3, pages 170–178, August 2015
How to Cite
Pradeep, A. R., Singh, S. P., Martande, S. S., Naik, S. B., N, P., Kalra, N. and Suke, D. K. (2015), Clinical and microbiological effects of levofloxacin in the treatment of chronic periodontitis: a randomized, placebo-controlled clinical trial. Journal of Investigative and Clinical Dentistry, 6: 170–178. doi: 10.1111/jicd.12091
- Issue published online: 20 JUL 2015
- Article first published online: 27 FEB 2014
- Manuscript Accepted: 24 NOV 2013
- Manuscript Received: 29 MAR 2013
- chronic periodontitis;
- clinical and microbiological effect;
- scaling and root planing
The aim of the present study was to evaluate the clinical and microbiological effect of systemic levofloxacin (LFX) as an adjunct to scaling and root planing (SRP) in patients with chronic periodontitis (CP).
Sixty-five patients with CP were randomly divided into a test (n = 33, SRP and LFX 500 mg, once daily [o.d.]) and a control group (n = 32, SRP and placebo, o.d.). Plaque index (PI), gingival index (GI), percentage of sites with bleeding on probing (%BoP), probing depth (PD), and clinical attachment level (CAL) were recorded at baseline, 10 days, and 1-, 3-, and 6-month intervals. The percentage of sites positive for Aggregatibacter actinomycetemcomitans (A. actinomycetemcomitans), Porphyromonas gingivalis, and Tannerella forsythia were recorded at baseline and at 3 and 6 months.
Patients receiving LFX showed statistically-significant improvements in mean PD and CAL. The intergroup difference in PI, GI, and%BoP was not significant at any interval. There was a reduction in the percentage of sites positive for periodontopathic bacteria over the duration of the study in both groups, and a statistically-significant reduction in the number of sites positive for A. actinomycetemcomitans in the LFX group (P < 0.001).
Levofloxacin was found to significantly improve the clinical and microbiological parameters in CP individuals.